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Abstract 
Background: Cryptogenic strokes can be attributed to paradoxical emboli through patent foramen 
ovale (PFO). However, the effectiveness of PFO closure in preventing recurrent stroke is uncertain and 
the results of previous randomized clinical trials (RCTs) have been inconclusive. Hence, this study pro-
vides an updated meta-analysis of all RCTs comparing PFO closure with medical therapy for secondary 
prevention of cryptogenic stroke.
Methods: All RCTs were identified by a comprehensive literature search of PubMed, Embase, the 
Cochrane Collaboration Central Register of Controlled Trials, Scopus, and Clinicaltrials.gov. The 
primary outcome was recurrent ischemic stroke and secondary outcomes were transient ischemic at-
tack (TIA), all-cause mortality, new-onset atrial fibrillation (AF), serious adverse events, and major 
bleeding. 
Results: Five RCTs with 3440 participants were included in the present study (1829 patients under-
went PFO closure and 1611 were treated medically). Pooled analysis showed a statistically significant 
reduction in the rate of recurrent stroke with PFO closure in comparison to medical therapy (OR 0.41; 
95% CI 0.19–0.90; p = 0.03). However, there were no statistically significant reductions of recurrent 
TIAs (OR 0.77; 95% CI 0.51–1.14; p = 0.19) or all-cause mortality (OR 0.76; 95% CI 0.35–1.65;  
p = 0.48). The risk of developing new-onset AF was increased significantly with PFO closure (OR 4.74; 
95% CI 2.33–9.61; p < 0.0001), but no significant differences in terms of serious adverse events or 
major bleeding between both groups.
Conclusions: Patent foramen ovale closure in adults with recent cryptogenic stroke was associated 
with a lower rate of recurrent strokes in comparison with medical therapy alone. (Cardiol J 2019; 26, 
1: 47–55)
Key words: patent foramen ovale, transcutaneous closure, septal occlude device, atrial 
tachyarrhythmia 
Introduction
Cryptogenic strokes are defined as any is-
chemic stroke that is not attributable to an iden-
tifiable cause despite an extensive work-up [1]. 
They represent 10% to 40% of all ischemic strokes 
[2, 3]. Although approximately 25% of the gen-
eral population has a benign patent foramen ovale 
(PFO), a fetal remnant of intraarterial septum [4], 
it can be found in up to 50% of adults younger than 
55 years of age with cryptogenic strokes [5]. 
Studies have shown a strong association between 
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the presence of PFO and the development of 
cryptogenic strokes, which suggests paradoxical 
embolism, through a right-to-left shunt, as a po-
tential mechanism [6, 7]. Therefore, an index was 
developed to differentiate incidental PFO from 
stroke-related PFO [8].
In addition, patients with established stroke in 
the setting of both PFO and atrial septal aneurysm 
have a significant increased risk for recurrent 
stroke and, therefore, other secondary preventive 
strategies than anti-thrombotic agents were sug-
gested [9]. Previous randomized controlled trials 
(RCTs) didn’t show a benefit of PFO closure over 
medical therapy [10, 11]. However, the results of 
recent RCTs showed promising evidence of a lower 
stroke recurrence rate among patients with recent 
cryptogenic stroke attributed to PFO [12–14].
In light of these new trials, it was undertaken 
to conduct an updated meta-analysis of all RCTs 
comparing transcutaneous device PFO closure 
with medical therapy for secondary prevention of 
cryptogenic strokes. In addition,  adverse events 
and complications associated with PFO closure 
were investigated.
Methods
Literature search and studies selection
Meta-analysis according to Preferred Re-
porting Items for Systematic Reviews and Meta-
Analyses Protocols (PRISMA-P) Statement 2015 
(Fig. 1) [15] were performed. Two authors (B.K. 
and A.A.), along with a third author (M.O.) for any 
discrepancies, independently conducted a com-
prehensive database search of PubMed, Embase, 
the Cochrane Collaboration Central Register of 
Controlled Trials, Scopus, Clinicaltrials.gov and 
conference proceedings from inception to Septem-
ber 2017. We used Boolean operators for connec-
tions of the following headings: “patent foramen 
ovale”, “PFO”, “percutaneous closure”, “humans” 
and “randomized clinical trials”. Only the longest 
follow-ups that compared device PFO closure with 
medical therapy were included. Meta-analysis 
was restricted only to RCTs as they carry less 
confounding biases in comparison to observational 
studies. Studies that fulfill the following criteria 
were included: 1) The study is an RCT; 2) The trial 
has PFO closure in one arm; 3) The duration of 
follow-up is at least 30 days; 4) The trial reported at 
least one of the following clinical outcomes: stroke 
or transient ischemic attack (TIA).
Data extraction
Two authors extracted the data (B.K., A.A.) 
and any discrepancies were resolved by a third 
author (M.O.). From each RCT, the following were 
extracted: baseline characteristics, adverse events, 
procedural and clinical outcomes (Tables 1, 2). 
The primary outcome of this meta-analysis was 
recurrent ischemic stroke. Secondary outcomes 
were TIA, all-cause mortality, new onset atrial 
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram; RCT — 
randomized clinical trial.
48 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
T
ab
le
 1
. D
et
ai
ls
 o
f t
he
 r
an
d
o
m
iz
ed
 c
lin
ic
al
 tr
ia
ls
.
C
ha
ra
ct
er
is
ti
cs
 
C
LO
S
U
R
E
 1
P
C
R
E
S
P
E
C
T
C
LO
S
E
G
o
re
 R
E
D
U
C
E
P
la
ce
 (s
ite
s)
U
S
A
 a
nd
 C
an
ad
a 
(8
7)
E
ur
o
p
e,
 C
an
ad
a,
 B
ra
zi
l, 
 
an
d
 A
us
tr
al
ia
 (2
9)
U
S
A
 a
nd
 C
an
ad
a 
(6
9)
Fr
an
ce
 (3
2)
 a
nd
  
G
er
m
an
y 
(2
) 
C
an
ad
a,
 D
en
m
ar
k,
 F
in
la
nd
, 
N
o
rw
ay
, S
w
ed
en
, t
he
 U
K
, 
an
d
 U
S
A
 (6
3)
P
ub
lic
at
io
n 
ye
ar
20
12
20
13
20
17
20
17
20
17
R
eg
is
tr
at
io
n 
N
C
T
00
20
14
61
N
C
T
00
16
62
57
N
C
T
00
46
52
70
N
C
T
00
56
22
89
N
C
T
00
73
88
94
S
p
o
ns
o
rs
 
N
M
T
 M
ed
ic
al
S
t. 
Ju
d
e 
M
ed
ic
al
S
t. 
Ju
d
e 
M
ed
ic
al
A
ss
is
ta
nc
e 
P
ub
liq
ue
  
—
 H
ô
p
ita
ux
 d
e 
P
ar
is
W
.L
. G
o
re
 a
nd
  
A
ss
o
ci
at
es
R
an
d
o
m
iz
at
io
n
C
lo
su
re
 v
s.
 m
ed
ic
al
  
—
 1
:1
C
lo
su
re
 v
s.
 m
ed
ic
al
C
lo
su
re
 v
s.
 m
ed
ic
al
  
—
 1
:1
C
lo
su
re
 v
s.
 a
nt
ip
la
te
le
t v
s.
 
an
tic
o
ag
ul
at
io
n 
—
 1
:1
:1
C
lo
su
re
 v
s.
 m
ed
ic
al
  
—
 2
:1
T
o
ta
l n
um
b
er
90
9
41
4
98
0
66
3
66
4
Fo
llo
w
-u
p
 [y
ea
rs
]
2
M
ea
n 
4.
1
M
ed
ia
n 
5.
9
M
ea
n 
5.
3 
±
 2
M
ed
ia
n 
3.
2
P
ri
m
ar
y 
en
d
p
o
in
t
In
ci
d
en
ce
 o
f T
IA
, s
tr
o
ke
, o
r 
m
or
ta
lit
y 
(a
ll-
ca
us
e 
m
or
ta
lit
y 
th
ro
ug
h 
th
e 
fir
st
 3
0 
d
ay
s 
 
al
l-c
au
se
 th
en
 n
eu
ro
lo
gi
ca
l 
m
o
rt
al
ity
 u
p
 to
 2
 y
ea
rs
)
C
o
m
p
o
si
te
 o
f d
ea
th
,  
no
nf
at
al
 s
tr
o
ke
, T
IA
,  
o
r 
p
er
ip
he
ra
l  
em
b
o
lis
m
C
o
m
p
o
si
te
 o
f r
ec
ur
re
nt
 
is
ch
em
ic
 s
tr
o
ke
 o
r 
ea
rl
y 
d
ea
th
 (w
ith
in
 3
0 
d
ay
s 
af
te
r 
im
p
la
nt
at
io
n 
o
f t
he
 d
ev
ic
e 
o
r 
45
 d
ay
s 
af
te
r 
 
ra
nd
o
m
iz
at
io
n)
O
cc
ur
re
nc
e 
o
f f
at
al
  
o
r 
no
nf
at
al
 s
tr
o
ke
1.
 F
re
ed
o
m
 fr
o
m
 c
lin
ic
al
 
ev
id
en
ce
 o
f a
n 
is
ch
em
ic
 
st
ro
ke
 a
t l
ea
st
 2
 y
ea
rs
 
2.
 In
ci
d
en
ce
 o
f n
ew
 b
ra
in
 
in
fa
rc
tio
n 
(c
o
m
p
o
si
te
  
o
f c
lin
ic
al
 is
ch
em
ic
 s
tr
o
ke
 
o
r 
si
le
nt
 b
ra
in
 in
fa
rc
tio
n)
E
ve
nt
s 
ra
te
, c
lo
su
re
5.
5%
3.
4
1.
8%
 (0
.6
6 
p
er
 1
00
  
p
at
ie
nt
-y
ea
rs
)
0
1:
 1
.4
%
 
2:
 5
.7
%
E
ve
nt
s 
ra
te
, m
ed
ic
al
 
th
er
ap
y
6.
8%
5.
2
3.
3%
 (1
.3
8 
p
er
 1
00
  
p
at
ie
nt
-y
ea
rs
)
6
1:
 5
.4
%
 
2:
 1
1.
3%
P
-v
al
ue
0.
37
0.
34
0.
15
7 
(0
.0
8)
<
 0
.0
01
1:
 0
.0
02
 
2:
 0
.0
4
C
LO
S
E
 —
 P
at
en
t F
o
ra
m
en
 O
va
le
 C
lo
su
re
 o
r 
A
nt
ic
o
ag
ul
an
ts
 v
er
su
s 
A
nt
ip
la
te
le
t T
he
ra
p
y 
to
 P
re
ve
nt
 S
tr
o
ke
 R
ec
ur
re
nc
e;
 C
LO
S
U
R
E
 1
 —
 E
va
lu
at
io
n 
o
f t
he
 S
T
A
R
Fl
ex
 S
ep
ta
l C
lo
su
re
 S
ys
te
m
 in
 P
at
ie
nt
s 
w
ith
  
a 
S
tr
ok
e 
an
d/
or
 T
ra
ns
ie
nt
 Is
ch
em
ic
 A
tt
ac
k 
du
e 
to
 P
re
su
m
ed
 P
ar
ad
ox
ic
al
 E
m
bo
lis
m
 th
ro
ug
h 
a 
Pa
te
nt
 F
or
am
en
 O
va
le
; 
G
or
e 
R
ED
U
C
E 
—
 G
O
R
E®
 H
EL
EX
®
 S
ep
ta
l O
cc
lu
de
r/
G
O
R
E®
 C
A
R
D
IO
FO
R
M
 S
ep
ta
l O
cc
lu
de
r 
an
d
 A
nt
ip
la
te
le
t M
ed
ic
al
 M
an
ag
em
en
t f
o
r 
R
ed
uc
tio
n 
o
f R
ec
ur
re
nt
 S
tr
o
ke
 o
r 
Im
ag
in
g-
C
o
nf
ir
m
ed
 T
IA
 in
 P
at
ie
nt
s 
W
ith
 P
at
en
t F
o
ra
m
en
 O
va
le
; 
P
C
 —
 C
lin
ic
al
 T
ri
al
 C
o
m
p
ar
in
g 
P
er
cu
ta
ne
o
us
 C
lo
su
re
 o
f P
at
en
t 
Fo
ra
m
en
 O
va
le
 (P
FO
) U
si
ng
 th
e 
A
m
p
la
tz
er
 P
FO
 O
cc
lu
d
er
 w
ith
 M
ed
ic
al
 T
re
at
m
en
t i
n 
P
at
ie
nt
s 
w
ith
 C
ry
p
to
ge
ni
c 
E
m
b
o
lis
m
; 
R
E
S
P
E
C
T
 —
 R
an
d
o
m
iz
ed
 E
va
lu
at
io
n 
o
f R
ec
ur
re
nt
 S
tr
o
ke
 C
o
m
p
ar
in
g 
P
FO
 C
lo
su
re
 
to
 E
st
ab
lis
he
d
 C
ur
re
nt
 S
ta
nd
ar
d
 o
f C
ar
e 
T
re
at
m
en
t;
 U
K
 —
 U
ni
te
d
 K
in
gd
o
m
; 
U
S
A
 —
 U
ni
te
d
 S
ta
te
s;
 T
IA
 —
 tr
an
si
en
t i
sc
he
m
ic
 a
tt
ac
k
www.cardiologyjournal.org 49
Babikir Kheiri et al., An updated meta-analysis of all randomized clinical trials
T
ab
le
 2
. B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
in
 th
e 
ra
nd
o
m
iz
ed
 c
o
nt
ro
l t
ri
al
s.
C
ha
ra
ct
er
is
ti
c 
C
LO
S
U
R
E
 1
P
C
R
E
S
P
E
C
T
C
LO
S
E
G
o
re
 R
E
D
U
C
E
C
lo
su
re
  
(n
 =
 4
47
)
M
ed
ic
al
  
(n
 =
 4
62
)
C
lo
su
re
  
(n
 =
 2
04
)
M
ed
ic
al
  
(n
 =
 2
10
)
C
lo
su
re
  
(n
 =
 4
99
)
M
ed
ic
al
  
(n
 =
 4
81
)
C
lo
su
re
  
(n
 =
 2
38
)
A
P
T
  
(n
 =
 2
35
)
C
lo
su
re
  
(n
 =
 4
41
)
M
ed
ic
al
  
(n
 =
 2
23
)
A
ge
 [y
ea
rs
]
46
.3
 ±
 9
.6
45
.7
 ±
 9
.1
44
.3
 ±
 1
0.
2
44
.6
 ±
 1
0.
1
45
.7
 ±
 9
.7
46
.2
 ±
 1
0.
0
42
.9
 ±
 1
0.
1
43
.8
 ±
 1
0.
5
45
.4
 ±
 9
.3
44
.8
 ±
 9
.6
M
al
e 
se
x
23
3 
(5
2.
1%
)
23
8 
(5
1.
5%
)
92
 (4
5.
1%
)
11
4 
(5
4.
3%
)
26
8 
(5
3.
7%
)
26
8 
(5
5.
7%
)
13
7 
(5
7.
6%
)
14
2 
(6
0.
4%
)
26
1 
(5
9.
2%
)
13
8 
(6
1.
9%
)
B
o
d
y 
m
as
s 
in
d
ex
–
–
26
.6
 ±
 5
.6
26
.3
 ±
 4
.8
–
–
32
 (1
3.
4%
) 
27
 (1
1.
5%
)
–
–
C
ig
ar
et
te
 s
m
o
ki
ng
 —
 
no
. o
f p
at
ie
nt
s/
to
ta
l n
o
. 
96
/4
47
  
(2
1.
5%
)
10
4/
46
0 
(2
2.
6%
)
52
 (2
5.
5%
)
47
 (2
2.
4%
)
75
 (1
5.
0%
)
55
 (1
1.
4%
)
68
 (2
8.
6%
)
69
 (2
9.
4%
)
63
 (1
4.
3%
)
25
 (1
1.
2%
)
H
yp
er
te
ns
io
n 
15
1 
(3
3.
8%
)
13
1 
(2
8.
4%
)
49
 (2
4.
0%
)
58
 (2
7.
6%
)
16
0 
(3
2.
1%
)
15
3 
(3
1.
8%
)
27
 (1
1.
3%
)
24
 (1
0.
2%
)
11
2 
(2
5.
4%
)
58
 (2
6.
0%
)
D
ia
b
et
es
 m
el
lit
us
–
–
5 
(2
.5
%
)
6 
(2
.9
%
)
33
 (6
.6
%
)
41
 (8
.5
%
)
3 
(1
.3
%
)
9 
(3
.8
%
)
18
 (4
.1
%
)
10
 (4
.5
%
)
H
yp
er
lip
id
em
ia
21
2 
(4
7.
4%
)
18
9 
(4
0.
9%
)
50
 (2
4.
5%
)
62
 (2
9.
5%
)
19
6 
(3
9.
3%
)
19
5 
(4
0.
5%
)
30
 (1
2.
6%
)
36
 (1
5.
3%
)
–
–
M
yo
ca
rd
ia
l i
nf
ar
ct
io
n
7 
(1
.6
%
)
5 
(1
.1
%
)
3 
(1
.5
%
)
1 
(0
.5
%
)
5 
(1
.0
%
)
2 
(0
.4
%
)
0
0
–
–
P
er
ip
he
ra
l v
as
cu
la
r 
d
is
ea
se
5 
(1
.1
%
)
7 
(1
.5
%
)
3 
(1
.5
%
)
2 
(1
.0
%
)
5 
(1
.0
%
)
1 
(0
.2
%
)
–
–
–
–
M
ig
ra
in
e 
–
–
47
 (2
3.
0%
)
38
 (1
8.
1%
)
19
5 
(3
9.
1%
)
18
6 
(3
8.
7%
)
67
 (2
8.
2%
)
78
 (3
3.
2%
)
–
–
C
ry
p
to
ge
ni
c 
st
ro
ke
 —
 
no
./t
o
ta
l n
o
. 
32
4/
44
6 
 
(7
2.
6%
)
32
9/
46
1 
(7
1.
4%
)
16
5 
(8
0.
9%
)
16
3 
(7
7.
6%
)
53
/4
98
 
(1
0.
6%
)
51
 (1
0.
6%
)
10
 (4
.2
%
)
7 
(3
.0
%
)
42
 (9
.5
%
) 
13
 (5
.8
%
)
T
IA
 —
 n
o
. o
f p
at
ie
nt
s/
 
/t
o
ta
l n
o
.
12
2/
44
6 
 
(2
7.
4%
)
13
2/
46
1 
(2
8.
6%
)
33
 (1
6.
2%
)
42
 (2
0.
0%
)
58
 (1
1.
6%
)
61
 (1
2.
7%
)
–
–
26
 (5
.9
%
)
11
 (4
.9
%
)
T
E
E
 —
 n
o
./t
o
ta
l:
La
rg
e 
43
/1
85
 
(2
3.
2%
)
37
/1
84
 
(2
0.
1%
)
79
/2
16
 
(3
6.
6%
)
M
o
d
er
at
e/
su
b
st
an
tia
l 
sh
un
t
25
0 
 
(5
5.
9%
)
23
1 
 
(5
0.
0%
)
24
7 
 
(4
9.
5%
)
23
1 
 
(4
8.
0%
)
La
rg
e/
no
 a
ne
ur
ys
m
15
7 
 
(6
6%
)
16
1 
 
(6
8.
5%
)
18
2/
42
5 
(4
2.
8%
)
La
rg
e/
an
eu
ry
sm
 
59
  
(2
4.
8%
)
62
  
(2
6.
4%
)
86
/4
22
 
(2
0.
4%
)
A
tr
ia
l s
ep
ta
l a
ne
ur
ys
m
 
≥ 
10
 m
m
16
8 
 
(3
7.
6%
)
16
5 
 
(3
5.
7%
)
47
  
(2
3.
0%
)
51
  
(2
4.
3%
)
18
0 
 
(3
6.
1%
)
17
0 
 
(3
5.
3%
)
N
A
P
lu
s–
m
in
us
 v
al
ue
s 
ar
e 
m
ea
ns
 ±
 s
ta
nd
ar
d
 d
ev
ia
tio
n.
 
A
P
T
 —
 a
nt
ip
la
te
le
t;
 C
LO
S
E
 —
 P
at
en
t F
o
ra
m
en
 O
va
le
 C
lo
su
re
 o
r 
A
nt
ic
o
ag
ul
an
ts
 v
er
su
s 
A
nt
ip
la
te
le
t T
he
ra
p
y 
to
 P
re
ve
nt
 S
tr
o
ke
 R
ec
ur
re
nc
e;
 C
LO
S
U
R
E
 1
 —
 E
va
lu
at
io
n 
o
f t
he
 S
T
A
R
Fl
ex
 S
ep
ta
l C
lo
su
re
 S
ys
te
m
 
in
 P
at
ie
nt
s 
w
ith
 a
 S
tr
ok
e 
an
d/
or
 T
ra
ns
ie
nt
 Is
ch
em
ic
 A
tt
ac
k 
du
e 
to
 P
re
su
m
ed
 P
ar
ad
ox
ic
al
 E
m
bo
lis
m
 th
ro
ug
h 
a 
Pa
te
nt
 F
or
am
en
 O
va
le
; 
G
or
e 
R
ED
U
C
E 
—
 G
O
R
E®
 H
EL
EX
®
 S
ep
ta
l O
cc
lu
de
r/
G
O
R
E®
 C
A
R
D
IO
FO
R
M
 
S
ep
ta
l O
cc
lu
d
er
 a
nd
 A
nt
ip
la
te
le
t M
ed
ic
al
 M
an
ag
em
en
t f
o
r 
R
ed
uc
tio
n 
o
f R
ec
ur
re
nt
 S
tr
o
ke
 o
r 
Im
ag
in
g-
C
o
nf
ir
m
ed
 T
IA
 in
 P
at
ie
nt
s 
W
ith
 P
at
en
t F
o
ra
m
en
 O
va
le
; 
P
C
 —
 C
lin
ic
al
 T
ri
al
 C
o
m
p
ar
in
g 
P
er
cu
ta
ne
o
us
  
C
lo
su
re
 o
f P
at
en
t F
o
ra
m
en
 O
va
le
 (P
FO
) U
si
ng
 th
e 
A
m
p
la
tz
er
 P
FO
 O
cc
lu
d
er
 w
ith
 M
ed
ic
al
 T
re
at
m
en
t i
n 
P
at
ie
nt
s 
w
ith
 C
ry
p
to
ge
ni
c 
E
m
b
o
lis
m
; 
R
E
S
P
E
C
T
 —
 R
an
d
o
m
iz
ed
 E
va
lu
at
io
n 
o
f R
ec
ur
re
nt
 S
tr
o
ke
  
C
o
m
p
ar
in
g 
P
FO
 C
lo
su
re
 to
 E
st
ab
lis
he
d
 C
ur
re
nt
 S
ta
nd
ar
d
 o
f C
ar
e 
T
re
at
m
en
t;
 T
E
E
 —
 tr
an
se
so
p
ha
ge
al
 e
ch
o
ca
rd
io
gr
ap
hy
; 
T
IA
 —
 tr
an
si
en
t i
sc
he
m
ic
 a
tt
ac
k;
 N
A
 —
 n
o
t a
va
ila
b
le
; 
no
. —
 n
um
b
er
50 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 1
tachyarrhythmia (atrial fibrillation [AF]), serious 
adverse events, and major bleeding.
Statistical analysis
Aggregate odds ratios (ORs) were calculated 
and 95% confidence intervals (CIs) using a random-
-effects model. The heterogeneity was measured 
using Cochran’s Q statistic (p < 0.05) and I2 statis-
tics. A random-effects model was used to account 
for between-study variation. P-value < 0.05 was 
considered statistically significant result. Data 
was analyzed with the intention-to-treat principle 
using RevMan, version 5.3 Windows (Cochrane 
Collaboration, Oxford, UK).
Results
Five RCTs with 3440 patients were included 
(54.97% male) with a mean age of 45.3 ± 9.7. 
1829 patients underwent PFO closure and 1611 
were treated medically. Pooled analysis showed 
a statistically significant reduction at the rate of 
recurrent ischemic stroke with device PFO closure 
in comparison with medical therapy (OR 0.41; 95% 
CI 0.19–0.90; p = 0.03). However, there were no 
statistically significant reductions of recurrent TIA 
(OR 0.77; 95% CI 0.51–1.14; p = 0.19) or all-cause 
mortality (OR 0.76; 95% CI 0.35–1.65; p = 0.48). 
The risk for new-onset AF in PFO closure was 
statistically significant (OR 4.74; 95% CI 2.33–9.61; 
p < 0.0001). In contrast, there were no significant 
differences in terms of serious adverse events 
(OR 1.07; 95% CI 0.91–1.25; p = 0.40) or major 
bleeding (OR 0.96; 95% CI 0.42–2.22; p = 0.93) 
(Fig. 2). The results of procedure outcomes can 
be found in Table 3.
In subgroup analyses an evaluation of potential 
heterogeneity of the treatment effect in relation to 
baseline covariates (Table 4), there may have been 
greater benefit of PFO closure versus medical ther-
apy in younger (< 45 years of age), male patients 
and patients with substantial shunt. However, 
there was no evidence of significant interaction of 
the treatment effect (all p ≥ 1.2 for interaction). In 
addition, new-onset AF was significantly increased 
in all PFO devices, including Amplatzer PFO 
Occluder (p ≤ 0.01) (Table 5).
Discussion
Cryptogenic strokes constitute about one-
third of all strokes, and approximately 60% are 
associated with PFO, which suggests paradoxical 
emboli via PFO shunt and/or in-situ thromboem-
bolism [16]. The present meta-analysis indicates 
that PFO closure is superior to medical therapy 
in patients < 60 years of age with recent PFO-
-related cryptogenic stroke. In addition, these 
results support prior meta-analyses of both pooled 
individual-patient and network analysis [17, 18], 
which demonstrated the benefit of device PFO clo-
sure over medical therapy for recurrent ischemic 
stroke events. 
Inconsistent results have been shown in the 
previous RCTs. The first RCT (CLOSURE 1) 
[10, 19] failed to demonstrate the benefit of PFO 
closure with the STARFlex device in preventing 
cryptogenic stroke over medical therapy alone. 
A similar result was obtained in the PC trial [11, 
20]. Although the rate of nonfatal ischemic stroke 
recurrence in the intention-to-treat analysis of 
the original RESPECT trial showed a statistically 
insignificant result (9 events in the closure group 
vs. 16 events in the medical therapy group; hazard 
ratio [HR] with closure, 0.49; 95% CI 0.22–1.11; 
p = 0.08), the between-group difference in the 
prespecified per-protocol cohort (6 events vs. 14 
events in the medical-therapy group; HR 0.37; 
95% CI 0.14–0.96; p = 0.03) and in the as-treated 
cohort (5 events vs. 16 events; HR 0.27; 95% CI 
0.10–0.75; p = 0.007) were significant [21]. The 
extended follow-up of the same trial (median of 5.9 
years) showed statistically significant results in 
the intention-to-treat population with 0.58 events 
in the closure group per 100 patient-years and 
1.07 events in the medical therapy group per 100 
patient-years (HR with PFO closure vs. medical 
therapy, 0.55; 95% CI 0.31–0.999; p = 0.046 by the 
log rank test) [13]. However, it should be noted that 
treatment exposure in both groups was unequal due 
to a higher dropout rate in the medical therapy arm 
(3141 patient-years in the closure group and 2669 
patient-years in the medical therapy group). Two 
other recent trials (CLOSE and Gore REDUCE) 
showed the superiority of PFO closure over medical 
therapy in lowering the rate of stroke recurrence 
[12, 14, 22]. In Gore REDUCE, there were different 
dropout rates, which could have biased the trial in 
relation to lower retention and thus attrition bias 
(8.8% discontinued the trial in the PFO closure 
vs. 14.8% in the antiplatelet group) [14]. Although 
previous reviews have suggested the benefits of 
oral anticoagulation over antiplatelet therapy for 
secondary prevention of PFO-related cryptogenic 
stroke [23], current guidelines voted for the use 
of antiplatelets only [24, 25]. Within this context, 
some trials have allowed the use of anticoagulants 
in the medical therapy group at the discretion of the 
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physicians which might have reduced the overall 
risk of cerebrovascular accident (CVA) in patients 
with undiagnosed thrombotic tendencies, a situation 
that could lead to a bias within the control group.
Previous studies have shown that recurrent 
CVA/TIA in patients with PFO may be related to 
mechanisms unrelated to paradoxical embolism and 
thus, PFO closure protects against PFO related 
mechanisms only [23]. In contrast, medical therapy 
can have a protective effect on recurrent CVA for 
both PFO related and unrelated events. Therefore, 
the reported recurrent CVA/TIA events in this 
meta-analysis could have included non-embolic 
events unrelated to PFO.
A common limitation among previous trials is 
the absence of prolonged cardiac monitoring for 
subclinical AF detection in patients with cryptogen-
ic stroke. Although occult AF is uncommon among 
patients < 60 years of age with cryptogenic stroke 
[26], the American Heart Association/American 
Stroke Association guidelines for stroke prevention 
recommends at least 30 days of cardiac monitoring 
in patients with no apparent cause of stroke/TIA 
to detect occult AF based on observational studies 
Figure 2. Forest plot of clinical outcomes; CI — confidence interval; TIA — transient ischemic attack.
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Table 3. Procedural outcomes in the randomized clinical trials.
Study Device used Index technical  
success*
Index procedural 
success**
Complete/effective 
closure  
(TEE grade 0/1)
CLOSURE 1 STARFlex (NMT Medical) — 89.4% 86.1% at 6 months 
86.7% at 24 months
PC Amplatzer PFO Occluder — 95.9% 95.9% at 6 months
RESPECT Amplatzer PFO Occluder 99.1% 96.1% 93.50% at 6 months 
72.70% at 6 months 
(complete)
CLOSE 11 different devices  
(Amplatzer PFO occluder  
n = 121/235)
99.6% 88.6% 93% at 10.8 months
Gore REDUCE 1. Helex Septal Occluder (HELEX; 
W.L. Gore and Associates) 
2. Cardioform Septal Occluder  
(GSO; W.L. Gore and Associates)
98.8% 73.2% 94.50% at 12 months 
75.6% at 12 months 
(complete)
*Technical success: delivery and release of the device. **Procedural success: implantation with no in-hospital complications. Abbreviations — 
see Tables 1 and 2
Table 4. Subgroups analyses to evaluate heterogeneity in relation to baseline covariates.
Subgroups PFO closure 
(events/total)
Medical therapy 
(events/total)
Odds ratio  
(95% CI)
P P for  
interaction
Age: 0.58
16–45 years 10/649 27/533 0.34 (0.16–0.71) 0.004
46–60 years 21/726 38/611 0.47 (0.18–1.24) 0.13
Gender: 0.23
Male 20/874 52/780 0.35 (0.15–0.81) 0.01
Female 26/704 20/478 0.75 (0.30–1.85) 0.53
Shunt size: 0.12
Substantial 12/839 34/630 0.27 (0.14–0.54) 0.0002
None, trace or moderate 29/667 45/679 0.65 (0.27–1.52) 0.31
Atrial septal aneurysm: 0.99
Present 7/226 15/221 0.63 (0.06–6.67) 0.70
Absent 18/477 24/470 0.65 (0.23–1.83) 0.41
Entry event:
Stroke 20/465 23/487 0.91 (0.49–1.69) 0.77 0.50
Transient ischemic attack 9/139 17/173 0.64 (0.27–1.48) 0.30
Cardiovascular disease history:
Present 2/98 8/102 0.29 (0.07–1.24) 0.09 0.92
Absent 5/344 17/343 0.24 (0.01–9.15) 0.44
Medical therapy: 0.55
Antiplatelet 25/653 39/252 0.82 (0.40–1.69) 0.58
Anticoagulation 9/157 13/232 1.19 (0.43–3.26) 0.74
CI — confidence interval; PFO — patent foramen ovale
Table 5. Subgroup analysis to evaluate the type of device occluder on the development of atrial  
tachy arrhythmia.
Device type PFO closure 
(events/total)
Medical therapy 
(events/total)
Odds ratio  
(95% CI)
P
Amplatzer PFO Occluder 28/703 11/691 2.54 (1.26–5.16) ≤ 0.01
Other PFO Occluders 52/843 4/681 10.61 (3.77–29.89) ≤ 0.01
CI — confidence interval; PFO — patent foramen ovale
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[25, 27]. A previous RCT (CRYSTAL AF) has sup-
ported the prolonged cardiac monitoring and the re-
sults showed that AF was more frequently detected 
in patients with recent cryptogenic stroke (12.4% 
detection rate in the monitored group vs. 2% in 
the unmonitored group; HR 7.3; 95% CI 2.6–20.8; 
p < 0.001) [28]. In addition, a meta-analysis of 
RCTs showed improved detection of AF after 
cryptogenic stroke/TIA with prolonged cardiac 
monitoring [29]. Therefore, even in the presence 
of PFO, AF should be considered as a potential 
cause of some presumptive cryptogenic strokes. 
In addition, lower than expected patient re-
cruitment was predominant among prior trials, 
which could have resulted in an extended recruit-
ment of very selected patients and, therefore, an 
unreliable population sample [11]. Additionally, 
on-treatment and per-protocol rates were not 
reported for adverse events in the previous tri-
als and thus safety analyses were not possible 
[30]. Furthermore, not all trials have reported all 
adverse events in their supplementary materials, 
which could mask other significant potential risks.
In the meta-analysis, a high association of 
PFO closure with new onset AF was found. The 
timing of AF was related to the PFO closure in 
different trials. For example, 91% of AF occurred 
in first month of PFO closure in the CLOSE trial, 
83% were detected within 45 days in the Gore 
REDUCE trial, and 61% were periprocedural in 
the CLOSURE trial. Such an association will need 
to be considered in treating PFO patients with 
percutaneous devices and their clinical relevance 
and overall CVA/TIA risk requires further inves-
tigation. It was assumed that an implanted PFO 
device may trigger a new focus for AF. Therefore, 
it may be suggested that a multidisciplinary and 
physician-patient clinical decision be made before 
proceeding with PFO closure when considering 
risks and benefits for such a procedure. In the 
RESPECT extended follow-up, a tendency for 
a higher venous thromboembolism rate was ob-
served in the PFO closure group, which, in part, 
might suggest a tendency of higher long-term risks 
of venous thromboembolism in patients with recent 
cryptogenic stroke [13]. Whether such an associa-
tion exists,  it may be suggested that a large pow-
ered RCT be used to examine the high tendency 
of thrombophilic phenomena in PFO.
The strength of this study is that only RCTs 
were included. The pooled analysis included a large 
number of populations from different backgrounds, 
despite prolonged recruitment, which could reflect 
a representative sample. Risks of atrial tachyar-
rhythmia across all trials along with other adverse 
events were also measured. In contrast, there are 
several limitations of this study. First, each trial 
allowed for different medical therapy strategies 
within their study groups and, therefore, the dif-
ferences within each study and across all RCTs 
may have affected the final results. Second, these 
results should not be generalized to patients other 
than those with recent PFO-related cryptogenic 
stroke ≤ 60 years of age. Third, different types of 
PFO devices were used across all trials and the 
efficacy and safety of each device should be consid-
ered when interpreting these results. Fourth, other 
factors such as left atrial size to detect the actual 
effect of different PFO devices on AF induction 
were not provided in the clinical trials to ascertain 
a cause-effect relationship. 
Conclusions
Meta-analysis of all RCTs showed that PFO 
closure was associated with a lower rate of recur-
rent ischemic strokes among adults who had had 
a recent cryptogenic stroke in comparison with 
medical therapy. However, PFO closure was asso-
ciated with an increased risk of developing a new 
onset atrial tachyarrhythmia.
Clinical perspectives
Competency in medical knowledge: PFO can 
be associated with cryptogenic strokes. The rate of 
recurrent stroke is relatively low. However, pooled 
results of RCTs showed lower recurrent strokes with 
PFO closure with associated higher risk of AF.
Translation outlook: Comparative studies 
of various types of PFO closure devices including 
their safety and efficacy are warranted. In addition, 
studies of antiplatelet and anticoagulant treatment 
regimens are needed to closeknowledge gaps.
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